In Oxford, the first volunteer received a vaccine against the Bundibugyo Ebola virus
In Oxford, the first volunteer received a vaccine against the Bundibugyo Ebola virus. When the world faces a new threat, science becomes the only shield capable of stopping its spread. The Bundibugyo Ebola virus, declared an international public health emergency, long remained without specific protective measures. But today, thanks to the efforts of Oxford scientists and their partners, humanity has taken the first step towards creating a vaccine against this deadly virus. Eight weeks – that is all it took to go from concept to clinical trials, proving that when science joins forces with determination, even the most complex challenges become surmountable.
On Friday, the University of Oxford announced the successful vaccination of the first volunteer in the world's first clinical trial of a vaccine designed to protect against the Bundibugyo Ebola virus. This marks the first administration of the ChAdOx1 vaccine against the Bundibugyo Ebola virus to a human. The vaccine was developed by scientists from the Oxford Vaccine Group and the university's Pandemic Sciences Institute. The research team will continue to recruit and vaccinate volunteers over the coming weeks, while monitoring participants to assess the vaccine's safety and the immune response it generates.
Researchers said the candidate vaccine went from concept to clinical trials in just eight weeks, thanks to collaboration between the University of Oxford's Clinical BioManufacturing Facility, the Serum Institute of India and other partners. The trial is funded by the Coalition for Epidemic Preparedness Innovations under an $8.6 million programme involving the University of Oxford and the Serum Institute of India to advance vaccine development against the Bundibugyo Ebola virus. According to the university, preparations are also under way for further clinical trials of the vaccine with partners in Uganda, subject to regulatory approval.
The Bundibugyo Ebola virus, named after the site of the first outbreak in the DRC, is one of six species of the Ebola virus and causes severe haemorrhagic fever with a high fatality rate. On 17 May, the World Health Organization (WHO) declared that the Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda constituted a public health emergency of international concern. There are currently no approved specific therapeutics or vaccines against the Bundibugyo virus.
As CCTV+ reports. The successful start of clinical trials offers hope that in the near future, medics will have an effective weapon against this dangerous infection, and international cooperation in vaccine development will continue to save lives around the world.
